Recruiting
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844· Phase 3· National Cancer Institute (NCI)· Source
Contact: Megan A. Baumgart
Active, not recruiting
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
NCT05863351· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
NCT06400251· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
NCT06400225· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
NCT06400238· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
NCT06360588· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
NCT06308822· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
NCT05490771· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
NCT06385483· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
NCT06390852· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
NCT04439227· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
NCT06136897· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)
NCT06385496· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
NCT06390865· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
NCT06390826· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
NCT06357975· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
NCT06360575· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
NCT06357988· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
NCT04439344· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
NCT04439123· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
NCT04439149· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
NCT04439188· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
NCT04439175· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
NCT04439357· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
NCT04439318· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
NCT06303167· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
NCT04439292· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
NCT04439331· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
NCT04439136· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
NCT04439279· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
NCT04439110· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
NCT04439266· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
NCT04439253· Phase 2· National Cancer Institute (NCI)· Source